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IMPORTANCE Understanding whether physicians accurately detect symptoms in patients

with breast cancer is important because recognition of symptoms facilitates supportive care,
and clinical trials often rely on physician assessments using Common Toxicity Criteria for
Adverse Events (CTCAE).
OBJECTIVE To compare the patient-reported outcomes (PROs) of patients with breast cancer

who received radiotherapy from January 1, 2012, to March 31, 2020, with physicians’ CTCAE
assessments to assess underrecognition of symptoms.
DESIGN, SETTING, AND PARTICIPANTS This cohort study included a total of 29 practices
enrolled in the Michigan Radiation Oncology Quality Consortium quality initiative. Of 13 725
patients with breast cancer who received treatment with radiotherapy after undergoing
lumpectomy, 9941 patients (72.4%) completed at least 1 PRO questionnaire during treatment
with radiotherapy and were evaluated for the study. Of these, 9868 patients (99.3%) were
matched to physician CTCAE assessments that were completed within 3 days of the PRO
questionnaires.
EXPOSURES Patient and physician ratings of 4 symptoms (pain, pruritus, edema, and fatigue)
were compared.
MAIN OUTCOMES AND MEASURES We used multilevel multivariable logistic regression to
evaluate factors associated with symptom underrecognition, hypothesizing that it would
be more common in racial and ethnic minority groups.
RESULTS Of 9941 patients, all were female, 1655 (16.6%) were Black, 7925 (79.7%) were
White, and 361 (3.6%) had Other race and ethnicity (including American Indian/Alaska Native,
Arab/Middle Eastern, and Asian), either as self-reported or as indicated in the electronic
medical record. A total of 1595 (16.0%) were younger than 50 years, 2874 (28.9%) were age
50 to 59 years, 3353 (33.7%) were age 60 to 69 years, and 2119 (21.3%) were 70 years or
older. Underrecognition of symptoms existed in 2094 of 6781 (30.9%) observations of
patient-reported moderate/severe pain, 748 of 2039 observations (36.7%) of patient-reported
frequent pruritus, 2309 of 4492 observations (51.4%) of patient-reported frequent edema, and
390 of 2079 observations (18.8%) of patient-reported substantial fatigue. Underrecognition
of at least 1 symptom occurred at least once for 2933 of 5510 (53.2%) of those who reported
at least 1 substantial symptom. Factors independently associated with underrecognition were
younger age (younger than 50 years compared with 60-69 years: odds ratio [OR], 1.35; 95% CI,
1.14-1.59; P < .001; age 50-59 years compared with 60-69 years: OR, 1.19; 95% CI, 1.03-1.37;
P = .02), race (Black individuals compared with White individuals: OR, 1.56; 95% CI 1.30-1.88;
P < .001; individuals with Other race or ethnicity compared with White individuals: OR, 1.52;
95% CI, 1.12-2.07; P = .01), conventional fractionation (OR, 1.26; 95% CI, 1.10-1.45; P = .002),
male physician sex (OR, 1.54; 95% CI, 1.20-1.99; P = .002), and 2-field radiotherapy (without
a supraclavicular field) (OR, 0.80; 95% CI, 0.67-0.97; P = .02).
CONCLUSIONS AND RELEVANCE The results of this cohort study suggest that PRO collection

may be essential for trials because relying on the CTCAE to detect adverse events may miss
important symptoms. Moreover, since physicians in this study systematically missed
substantial symptoms in certain patients, including younger patients and Black individuals
or those of Other race and ethnicity, improving symptom detection may be a targetable
mechanism to reduce disparities.
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T

oxic effects of cancer therapy can impair patients’ quality of life and may sometimes limit the ability to deliver
treatments optimally to ensure disease control. Understanding whether physicians are adequately detecting when
patients are experiencing substantial toxic effects is important because recognition of symptoms is a necessary precondition to delivering adequate supportive care.1,2
In the context of clinical trials and data registries, recognition of symptoms is also important because it affects the
broader understanding of patient experiences with various
treatments. The generalizable knowledge derived from trials
and registries affects the treatment decisions made by other
clinicians and patients in the future, so the accuracy of information collected in those settings merits scrutiny. Several prior
studies have raised questions about whether physician ratings of toxic effects accurately capture patient experiences.3-6
Recently, we reported finding differences between White
individuals and individuals in racial and ethnic minority groups
regarding the short-term toxic effects of treatment with radiotherapy for breast cancer, with Black patients more likely
to experience pain during adjuvant therapy in a large multicenter prospective cohort in the US.7 Because this data set includes information from physician and patient reports, we
more recently initiated an analysis to evaluate whether treating physicians were recognizing symptoms when patients were
reporting substantial toxic effects and whether this varied
by patient or clinician characteristics. We hypothesized that
physicians’ underrecognition of toxic effects would be particularly pronounced among patients from racial and ethnic
minority groups, and we report our findings in this article.

Methods
Patients with breast cancer who received treatment with radiotherapy after undergoing lumpectomy at 29 practices were
enrolled in a quality initiative, the Michigan Radiation Oncology Quality Consortium (MROQC). The MROQC received
institutional review board approval from the University of
Michigan Medical School as a quality improvement initiative
with an informed consent waiver because the primary purpose of data collection was for quality improvement rather than
research, and its structure has been detailed elsewhere.8,9
In brief, detailed information was collected through this initiative for all patients receiving adjuvant whole breast radiotherapy for nonmetastatic unilateral breast cancer in participating practices. Weekly during treatment, physicians submitted
toxic effect evaluations using standard forms that contained detailed relevant measures from the Common Toxicity Criteria
for Adverse Events (CTCAE), version 4.0. Patients are also asked
to participate in voluntary weekly patient-reported outcomes
(PROs) assessments during treatment.
Of 13 725 female patients who completed radiotherapy
between January 1, 2012, and March 31, 2020, 9941 (72.4%)
completed at least 1 PRO questionnaire during radiotherapy.
When physician assessments were available within 3 days of
patient-reported evaluation, patient and physician ratings
of 4 symptoms were compared.
E2

Key Points
Question Do physicians accurately detect treatment-associated
toxic effect symptoms in patients with breast cancer?
Findings In this cohort study of 13 725 patients with breast cancer
who received treatment with radiotherapy after undergoing
lumpectomy, when patient reports were compared with matched
physician reports for 9868 patients, more than half of those
patients experiencing substantial acute toxic effect symptoms
during radiotherapy had symptoms that were underrecognized by
physicians during their treatment course (2933 of 5510). Factors
independently significantly associated with underrecognition
were younger age, Black or Other race and ethnicity (including
American Indian/Alaska Native, Arab/Middle Eastern, and Asian),
conventional fractionation, male physician sex, and 2-field
radiotherapy.
Meaning The findings of this study suggest that physicians may
systematically miss substantial symptoms in certain patients,
particularly patients who are young or Black individuals or those
of Other race and ethnicity; improving symptom detection may
be a targetable mechanism to reduce disparities in experiences
and outcomes.

Patients reported breast pain via an approved modification of the Brief Pain Inventory,10 asking for ratings in the last
24 hours of pain at its worst, least, average, and “right now.”
Substantial pain was defined as moderate or severe pain reported by patients. Physicians were deemed to underrecognize pain when patients reported moderate pain (score, 4-6)
but physicians graded pain as 0 (absent) on the CTCAE, or when
patients reported severe pain (score, 7-10) but physicians’
CTCAE grade was 1 or less.
Patients reported bother from pruritus and edema of
the breast using modified scaled measures adapted from the
Skindex instrument.11 To evaluate bother from pruritus, patients were asked, “During the past week, how often have you
been bothered by itching of the skin of the treated breast?”
To evaluate bother from edema, patients were asked, “During the past week, how often have you been bothered by swelling of the treated breast?” Response options were never, rarely,
sometimes, often, or all of the time. Physicians were deemed
to underrecognize pruritus and edema if they graded these as
absent (grade 0) when patients reported substantial symptoms (defined as bother often or all of the time from itching
or swelling, respectively).
Finally, patients reported fatigue as described previously,9
using a single item asked on the end-of-treatment questionnaire: “How often did you feel significant fatigue?” Response
options were always, most of the time, sometimes, rarely, or
never during the past 4 weeks. Physicians were deemed to underrecognize fatigue if they graded fatigue as absent (grade 0)
when patients reported having substantial symptoms (defined as significant fatigue most of the time or always).
In our analyses, after describing the association between
physician and patient pain scores and calculating the Spearman
rank correlation, we reported the patterns of underrecognition
for each substantial symptom. We then described the proportion of patients who experienced substantial symptoms for
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Results
eTable 1 in Supplement 1 provides the characteristics of the
9941 patients who completed at least 1 PRO questionnaire; it
provides a comparison of those who experienced at least 1 form
of substantial toxic effects with those who did not, similar to
a previously reported analysis.7 Of the patients, 1655 (16.6%)
were Black, 7925 (79.7%) were White, and 361 (3.6%) had Other
race. Nearly half (4469 [45%]) were younger than 60 years. In
this sample, 3434 of 9940 patients (34.5%) who had at least
1 patient-reported pain assessment reported substantial breast

Figure 1. Percentage of Observations With Underrecognized Symptoms
100

Observations with underrecognized
symptoms, %

whom underrecognition of at least 1 of these 4 symptoms
occurred at least once during the treatment course. We used
multilevel multivariable logistic regression modeling to evaluate factors that were associated with a patient experiencing
this underrecognition and test the hypothesis that it would be
a more common experience for racial and ethnic minority
groups.
We include as fixed effects in the model the following
covariates: age group (<50, 50-59, 60-69, and ≥70 years), body
mass index (calculated as weight in kilograms divided by height
in meters squared) category (underweight [<18.5], normal [18.5<25], overweight [25 to <30], obesity I [30 to <35], obesity II
[35 to <40], and obesity III [≥40]), racial and ethnic group
(Black, White, or Other [(including American Indian/Alaska
Native, Arab/Middle Eastern, and Asian]), use of a supraclavicular nodal field (yes/no), radiation dose fractionation (conventional [1.8-2 Gy]/hypofractionation [>2-2.8 Gy]), use of a
lumpectomy bed boost (yes/no), whether the treating site was
an academic facility (teaching resident/fellows: yes/no), and
the sex of the treating radiation oncologist (female/male). As
random effects, patients were clustered by treating radiation
oncologist, and patients and radiation oncologists were clustered by treating facility. Race and ethnicity were based on selfreport for the 5006 of 5510 (91% of the modeled population)
who provided this information directly via surveys, and the
remainder were based on information in the electronic medical record. Black race included patients who indicated Black
or African American, and Other included all other racial identities (within which the largest subcategory was Asian, followed by Arab/Middle Eastern, followed by American Indian/
Alaska Native; these groups were combined as each did not,
individually, contain enough patients to permit meaningful
or generalizable results).
We used a 3-level multilevel model for describing the association of these variables, with underrecognition of shortterm toxic effects by the physician when substantial symptoms were reported by the patient, at the bivariate level (single
fixed-effects explanatory variable plus the clustering effects)
and for the multivariable model (including all fixed-effects explanatory variables plus clustering effects simultaneously). All
statistical analyses were conducted using SAS, version 9.4
(SAS Institute). P values at or less than .05 were considered significant except in the presence of multiple testing, when
significant P values were compared with .05/the number of
tests (Bonferroni correction).
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pain. Of 9923 who received at least 1 patient-reported assessment of bother from pruritus, 3039 (30.6%) reported frequent bother from pruritus. Of 9906 who had at least 1 patientreported assessment of bother from edema, 2363 (23.9%)
reported frequent bother from edema. Finally, of 8860 who
responded regarding fatigue, 2209 (24.9%) reported substantial fatigue.
We could evaluate underrecognition in 9868 patients, with
37 593 independent paired observations of patient and physician reports. Of these, 35 797 observations (95.2%) occurred
on the exact same date, and 1796 (4.8%) occurred within 3 days.
Detailed findings from an analysis of concordance between
physician and patient reports of pain is provided in eTable 2
in Supplement 1. This demonstrated a strong association between patient and physician ratings, with a Spearman rank correlation between physician CTCAE and patient score groups
of 0.58 (P < .001). Nevertheless, as shown in Figure 1, underrecognition existed in 2094 of 6781 observations (30.9%) of
patient-reported moderate or severe pain, 748 of 2039 (36.7%)
of patient-reported frequent bother from pruritus, 2309 of 4492
(51.4%) of patient-reported frequent bother from edema, and
390 of 2079 (18.8%) of patient-reported substantial fatigue.
The Table presents the characteristics of the 5510 unique
patients who reported experiencing at least 1 substantial symptom during treatment with radiotherapy who constitute the
sample in which evaluation of underrecognition of substantial symptoms is possible. Underrecognition of at least 1 of
the 4 symptoms occurred at least once during the patient’s
treatment course for 2933 of 5510 patients (53.2%) who reported at least 1 substantial symptom during treatment with
radiotherapy.
Results of the bivariate analyses are presented in Figure 2.
Factors significantly associated with underrecognition, comparing P values with a multiple testing corrected significance
value of .00625, were patient age (Age <50 years vs 60-69: odds
ratio [OR], 1.43; 95% CI, 1.21-1.67; P < .001), race and ethnicity (Black vs White individuals: OR, 1.63; 95% CI, 1.37-1.95;
P < .001; individuals of Other race and ethnicity vs White
individuals: OR, 1.62; 95% CI, 1.19-2.20; P < .001), dosefractionation (conventional fractionation vs hypofractionation: OR, 1.24; 95% CI, 1.10-1.40; P = .001), and attending

jamaoncology.com

(Reprinted) JAMA Oncology Published online April 21, 2022

© 2022 American Medical Association. All rights reserved.

Downloaded From: https://jamanetwork.com/ by a Henry Ford Health System User on 05/13/2022

E3

Research Original Investigation

Identifying Patients Whose Symptoms Are Underrecognized During Treatment With Breast Radiotherapy

Table. Characteristics of the 5510 Patients Who Experienced at Least 1 Substantial Symptom
During Treatment With Breast Radiotherapy
No. (column %) [row %]

All (n = 5510),
No. (column %)

Underrecognition occurred
at least once when
substantial symptom
reported (n = 2951)

No underrecognition
(n = 2559)

<50

1115 (20.2)

656 (22.2) [58.8]

459 (17.9) [41.2]

50-59

1799 (32.7)

988 (33.5) [54.9]

811 (31.7) [45.1]

60-69

1704 (30.9)

854 (28.9) [50.1]

850 (33.2) [49.9]

≥70

892 (16.2)

453 (15.4) [50.8]

439 (17.2) [49.2]

Underweight (<18.5)

95 (1.7)

44 (1.5) [46.3]

51 (2.0) [53.7]

Normal (18.5 to <25)

1144 (20.8)

592 (20.1) [51.7]

552 (21.6) [48.3]

Overweight (25 to <30)

1574 (28.6)

829 (28.1) [52.7]

745 (29.1) [47.3]

I (30 to <35)

1276 (23.2)

691 (23.4) [54.2]

585 (22.9) [45.8]

II (35 to <40)

749 (13.6)

414 (14.0) [55.3]

335 (13.1) [44.7]

III (≥40)

672 (12.2)

381 (12.9) [56.7]

291 (11.4) [43.3]

Black

1066 (19.3)

715 (24.2) [67.1]

351 (13.7) [32.9]

White

4240 (77.0)

2108 (71.4) [49.7]

2132 (83.3) [50.3]

Other

204 (3.7)

128 (4.3) [62.7]

76 (3.0) [37.3]

No

4774 (86.6)

2570 (87.1) [53.8]

2204 (86.1) [46.2]

Yes

736 (13.4)

381 (12.9) [51.8]

355 (13.9) [48.2]

Conventional

2975 (54.0)

1643 (55.7) [55.2]

1332 (52.1) [44.8]

Hypofractionated

2535 (46.0)

1308 (44.3) [51.6]

1227 (48.0) [48.4]

No

680 (12.3)

349 (11.8) [51.3]

331 (12.9) [48.7]

Yes

4830 (87.7)

2602 (88.2) [53.9]

2228 (87.1) [46.1]

No

3486 (63.3)

1782 (60.4) [51.1]

1704 (66.6) [48.9]

Yes

2024 (36.7)

1169 (39.6) [57.8]

855 (33.4) [42.2]

Female

1939 (35.2)

1001 (33.9) [51.6]

938 (36.7) [48.4]

Male

3571 (64.8)

1950 (66.1) [54.6]

1621 (63.3) [45.4]

Variable/level
Age group, y

BMI category

Obesity

Racial and ethnic groupa

Supraclavicular field used

Fractionation

Boost used

Academic treatment facility

Sex of treating clinician

physician sex (male vs female physicians: OR, 1.50; 95% CI,
1.16-1.94; P = .004).
On multivariable modeling, as shown in Figure 3, the factors independently associated with underrecognition were
younger age (younger than 50 years compared with 60-69
years: odds ratio [OR], 1.35; 95% CI, 1.14-1.59; P < .001; age 50-59
years compared with 60-69 years: OR, 1.19; 95% CI, 1.03-1.37;
P = .02), race (Black individuals compared with White individuals: OR, 1.56; 95% CI 1.30-1.88; P < .001; individuals
with Other race compared with White individuals: OR, 1.52;
95% CI, 1.12-2.07; P = .01), conventional fractionation OR, 1.26;
95% CI, 1.10-1.45; P = .002), and male physician sex (OR, 1.54;
95% CI, 1.20-1.99; P = .002). In addition, on multivariable
analysis, receiving a supraclavicular field was independently
associated with lower odds of underrecognition (OR, 0.80; 95%
CI, 0.67-0.97; P = .02). Calculation of the intraclass correlation coefficients demonstrated that the clustering of patients
E4

Abbreviation: BMI, body mass index
(calculated as weight in kilograms
divided by height in meters squared).
a

Racial and ethnic identities are
based on self-report for 91% who
completed surveys asking their race
and ethnicity and from electronic
medical records for the remainder.
Black includes patients who
indicated “Black” or “African
American”; Other includes all other
racial and ethnic identities (in which
the largest subgroup was Asian,
followed by Arab/Middle Eastern,
followed by American Indian/Alaska
Native).

within physicians and facilities explained only 6.84% of the
overall variance in underrecognition, of which 4.33% was because of physician-level clustering and 2.51% because of facilitylevel clustering.

Discussion
In this cohort study using a large prospective observational data
set, meaningful differences in patient and physician reports
of short-term toxic effects existed. More than half of all patients who experienced a substantial short-term toxic effect
symptom based on their own report did not have timely recognition of that symptom by their physician. Particularly worrisome is the finding that underrecognition of substantial symptoms was most common in patients of racial and ethnic
minority groups, even after controlling for other differences
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Figure 2. Bivariate Associations for the Fixed-Effects Explanatory Variables

Study

Favors no
underrecognition

OR
(95% CI)

P value

Favors
underrecognition

Age group, y

<.001

<50

1.43 (1.21-1.67)

50-59

1.20 (1.05-1.38)

60-69

1 [Reference]

≥70

0.98 (0.82-1.16)

Race and ethnicitya

<.001

White

1 [Reference]

Black

1.63 (1.37-1.95)

Other

1.62 (1.19-2.20)

BMI category

.69

Underweight (<18.5)

0.81 (0.52-1.25)

Normal weight (18.5 to <25)

0.98 (0.84-1.15)

Overweight (25 to <30)

1 [Reference]

Obesity I (30 to <35)

1.04 (0.89-1.22)

Obesity II (35 to <40)

1.04 (0.87-1.25)

Obesity III (≥40)

1.11 (0.92-1.35)

P = .00625 considered significant
because of multiple testing. BMI
indicates body mass index (calculated
as weight in kilograms divided by
height in meters squared).
a

Supraclavicular nodal field: yes vs no

0.92 (0.78-1.09)

.33

Conventional fractionation: yes vs no

1.24 (1.10-1.40)

.001

Lumpectomy bed boost: yes vs no

1.06 (0.89-1.28)

.50

Center: academic vs community

1.31 (0.89-1.94)

.16

Sex of physician: male vs female

1.50 (1.16-1.94)

.004
0.1

1

10

OR (95% CI)

Racial and ethnic identities are
based on self-report for 91% who
completed surveys asking their race
and ethnicity and from electronic
medical records for the remainder.
Black includes patients who
indicated “Black” or “African
American”; Other includes all other
racial and ethnic identities (in which
the largest subgroup was Asian,
followed by Arab/Middle Eastern,
followed by American Indian/Alaska
Native).

Figure 3. Multiple Variable Associations for the Fixed-Effects Explanatory Variables

Study

Favors no
underrecognition

OR
(95% CI)

P value

Favors
underrecognition

Age group, y

.001

<50

1.35 (1.14-1.59)

50-59

1.19 (1.03-1.37)

60-69

1 [Reference]

≥70

0.98 (0.83-1.17)

Race and ethnicitya

<.001

White

1 [Reference]

Black

1.56 (1.30-1.88)

Other

1.52 (1.12-2.07)

BMI category

.85

Underweight (<18.5)

0.80 (0.52-1.23)

Normal weight (18.5 to <25)

0.96 (0.82-1.13)

Overweight (25 to <30)

1 [Reference]

Obesity I (30 to <35)

1.01 (0.86-1.18)

Obesity II (35 to <40)

1.01 (0.84-1.21)

Obesity III (≥40)

1.06 (0.87-1.28)

P < .05 considered significant.
BMI indicates body mass index
(calculated as weight in kilograms
divided by height in meters squared).
a

Supraclavicular nodal field: yes vs no

0.80 (0.67-0.97)

.02

Conventional fractionation: yes vs no

1.26 (1.10-1.45)

.002

Lumpectomy bed boost: yes vs no

0.93 (0.77-1.13)

.45

Center: academic vs community

1.26 (0.85-1.86)

.24

Sex of physician: male vs female

1.54 (1.20-1.99)

.002
0.1

1

10

OR (95% CI)

in patient and treatment characteristics and the clustering of
patients within treating physicians and facilities.
Several other studies have suggested that physicians may
underrecognize symptoms that trouble their patients and that
patient-reported outcomes measures are more likely to reveal
serious toxic effects than clinician reports.4-6 In the trial NRG
1203,3 clinicians were found to have substantially underreported

Racial and ethnic identities are
based on self-report for 91% who
completed surveys asking their race
and ethnicity and from electronic
medical records for the remainder.
Black includes patients who
indicated “Black” or “African
American”; Other includes all other
racial and ethnic identities (in which
the largest subgroup was Asian,
followed by Arab/Middle Eastern,
followed by American Indian/Alaska
Native).

symptomatic gastrointestinal adverse events compared with
patients themselves, with important implications for the primary
outcome of the research. However, others have shown higher
levels of agreement between physician-reported and patientreported outcomes.12 The current study focused on the clinically
meaningful question of whether there was timely recognition
of substantial symptoms, with disappointing findings.
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Prior studies have documented that patients of racial and
ethnic minority groups experience higher rates of short-term
toxic effects.7 Although some of this difference might be associated with biological differences in genes associated with
inflammation, wound repair, and fibrotic response or other effects of radiation,13,14 racial and ethnic disparities in experiences likely also reflect differences in social factors, including resources and behaviors.15 Black patients are less likely to
receive hypofractionated radiation therapy,16 an approach less
likely to be followed by short-term toxic effects,9 but the association between race and ethnicity and toxic effects in the
current study existed even after controlling for differences in
fractionation. Given evidence that clinicians may be less sensitive to pain experienced by Black patients and less likely to
prescribe them pain medication,17-26 and also given that skin
reactions to radiation may be less easily observed in patients
with darker skin pigmentation and physicians may be less
familiar with the ways radiation dermatitis manifests in patients with darker skin tones,27 we hypothesized that underrecognition of symptoms would be more likely for individuals of racial and ethnic minority groups. This study’s findings
confirmed that hypothesis.
Higher underrecognition of short-term toxic effects among
individuals of racial and ethnic minority groups may reflect differences in the resources available to clinicians who serve primarily racial and ethnic minority groups. However, these findings persisted even after a multivariable analysis that adjusted
for clustering of patients within clinicians and facilities. Moreover, the intraclass correlation coefficients suggested that most
of the variance in underrecognition was associated with individual patient-level factors, including patient race and ethnicity, rather than differences at the level of the clinicians or
facilities where they receive care.
Differences in clinician recognition of symptoms by
patient race and ethnicity are not necessarily the result of
differences in the skills or behavior of these physicians. Racism has understandably led to distrust of the health care system by many in racial and ethnic minority groups.28-36 Those
who have repeatedly faced undertreatment of pain25,37-41
might reasonably assume that health care clinicians are
unlikely to help and be less likely to mention symptoms in a
different context. Those who are socioeconomically underserved may be less likely to have a family member who can
take time off to accompany them on their visits, potentially
changing the likelihood that concerns are brought to the
physician’s attention. Thus, even if all of the physicians in
this study treated patients they encountered in an unbiased
way, differences in recognition of symptoms could nevertheless emerge.
That said, changes in clinician behaviors may still be essential to increase the trustworthiness of the health care system. The current study identifies a remediable deficit: a gap
in communication about symptoms. Because this deficit is
more pronounced in patients of racial and ethnic minority
groups, this is not only a target for general quality improvement but also mitigation of disparities in oncology care. Promoting the engagement of nursing and other support staff and
optimizing communication within interdisciplinary teams reE6

garding symptom identification and supportive care delivery
is a promising way forward.42
In addition to underrecognition being more common for
patients of racial and ethnic minority groups, underrecognition was more common in younger patients, those who did not
receive a supraclavicular field, and those who received conventional fractionation. Perhaps physicians may be most vigilant in asking about and recognizing short-term toxic effects
when encountering patients they perceive to be at highest risk
for toxic effects. Underrecognition was also more common in
those seen by male physicians. Prior research has shown that
female physicians may have different communication styles
and spend more time in direct patient care per visit.43 Further research is necessary to identify what physician behaviors optimize the accurate communication of information about
the toxic effects of patients.

Limitations
The limitations of this study include its situation within a
single state within the US; given the social construction of
race and ethnicity, differences may vary in other parts of the
US and the world. Other limitations include the difficulty of
using observational data of this sort to understand root
causes of observed differences. We lacked sufficient data on
factors like socioeconomic status that might explain some of
the associations observed. Finally, there are many ways that
agreement between patient and physician reports can be
assessed. We attempted to focus on a meaningful form of
underrecognition for clinical care delivery: timely recognition of severe symptoms at least once during the patient’s
treatment course. We deliberately limited our analyses to
this prespecified measure to minimize erroneous inferences
associated with multiplicity of testing. Additionally, the
analyses of clinician and facility characteristics was limited
to sex and teaching institution status, and factors were not
able to be assessed for the subgroups included in Other race
and ethnicity. Additional research to collect other clinician
characteristics, such as clinician race and ethnicity, and to
investigate any association of patient-clinician racial and
ethnic concordance, might also be a valuable endeavor in
the future.

Conclusions
In this cohort study, PRO collection appeared essential for trials
because relying on the CTCAE to detect adverse events may
miss important symptoms. Moreover, since in this study physicians seemed to systematically miss substantial symptoms
in certain patients, including those who were younger or of racial and ethnic minority groups, improving symptom detection may be a targetable mechanism to reduce disparities in
radiotherapy experiences and outcomes. Promising efforts to
facilitate routine PRO collection during and after treatment via
electronic platforms are already underway.44 For now, all physicians should inquire directly about potential toxic effects in
detail with all patients to avoid missing symptoms they might
help to mitigate.
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